

## MEDESIS PHARMA: PATENT REGISTERED IN EURASIA TO PROTECT THE CESIUM DECORPORATION DRUG CANDIDATE

Montpellier, December 12, 2022 - 6pm — MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates with Aonys®, its proprietary buccal nanodroplet active ingredient administration technology, is today announcing that the Eurasian Office has confirmed registration of the patent protecting the drug candidate NU02 NanoPB developed with the Aonys® technology for Cesium decorporation following a civil or military nuclear accident.

This patent, filed in July 2016, has already been registered in Japan and the United States and its registration is underway in Europe, China, Canada and Israel. It is now registered with the Eurasian Patent Office (EPO) under number 201890255 with effect from November 2, 2022. The Eurasian patent will cover the territory of all the states that have signed up to the Eurasian Patent Convention, i.e.: Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russian Federation, Tajikistan and Turkmenistan.

For several years, Medesis Pharma has been developing three drug candidates for the treatment of large populations that have been irradiated and/or contaminated following a nuclear explosion. They have been developed in collaboration with the French Atomic Energy Commission (LRT-CEA), which carried out all the studies on animals contaminated by radionuclides, and with the French Armed Forces Biomedical Research Institute (IRBA) for studies on irradiated animals.

The drug candidate protected by the Eurasian patent, **NU02: NanoPB (Prussian Blue)**, enables rapid Cesium decorporation following a nuclear accident.

Cesium 137 emits beta and gamma radiation. Beta radiation travels short distances and can penetrate the skin and superficial body tissue, while gamma radiation can travel large distances and penetrate the entire body. Cesium is fixed preferentially in the muscles and particularly the heart muscle, causing cardiac pathologies and abnormalities in children and adolescents.

Following the Chernobyl accident (1986) (WHO, Health Effects of the Chernobyl Accident, Geneva 2006), "children" included people exposed as infants, children and adolescents. The following pathologies have very high frequency rates among children who were exposed: thyroid disorders (cancer), leukemias, solid cancers; non-cancer effects: cataract genesis, cardiovascular diseases; immunological effects, reproductive effects, mental effects, psychological effects and impacts on the central nervous system.

Prussian Blue has been used for many years for Cesium extraction. It is administered in large 500mg capsules, with 18 capsules per day for two to three months. Impossible to dissolve, it is almost impossible to give to children and adolescents and is accompanied by obstinate constipation, resulting in irradiation of the lower pelvis.

The NanoPB, developed by Medesis Pharma, consists of Prussian Blue nanoparticles synthesized and stabilized in the Aonys microemulsion. It makes it possible to achieve cesium decorporation three times faster with 100 times less Prussian Blue. It is drinkable and suitable for administration at any age, including infants and children.

After funding was rejected by the French Ministry of Defense in July this year, the drug candidate and the two other products (NU02 — Cesium decorporation, NU01 - Plutonium decorporation and NP02 — NanoManganese radioprotection) will be submitted in 2023 for funding in the United States, with support from the two new American members of Medesis Pharma's Supervisory Board.

### About Medesis Pharma

To advance the treatment of serious diseases without effective treatments, Medesis Pharma creates drug candidates based on its proprietary Aonys® technology for the oral administration of active ingredients in nanodroplet form, enabling active ingredients to be effectively delivered to all cells, with passage through the blood-brain barrier (BBB).

This innovative approach is being applied to future drugs to treat major diseases that do not have effective treatments: Alzheimer's disease, Huntington's disease, and certain resistant cancers.

Medesis Pharma is also developing treatments dedicated to populations contaminated or irradiated after a civil or military nuclear accident.

French biopharmaceutical company based near Montpellier, Medesis Pharma is the author of 15 scientific publications, holds 11 patent families and 71 patents, the result of 17 years of research.

Medesis Pharma's shares are listed on Euronext Growth Paris: FR001844464 - ALMDP

### For more information:

[www.medesispharma.com](http://www.medesispharma.com)

### MEDESIS PHARMA

Tessa Olivato  
Tel: +33 4 67 03 03 96  
[contact@medesispharma.com](mailto:contact@medesispharma.com)

### CALYPTUS

Marie Calleux  
Tel : +33 1 53 65 68 66  
[medesispharma@calyptus.net](mailto:medesispharma@calyptus.net)